HomeCompareSVFD vs PFE

SVFD vs PFE: Dividend Comparison 2026

SVFD yields 141.84% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SVFD wins by $18.82M in total portfolio value
10 years
SVFD
SVFD
● Live price
141.84%
Share price
$1.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.87M
Annual income
$7,907,394.84
Full SVFD calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SVFD vs PFE

📍 SVFD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSVFDPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SVFD + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SVFD pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SVFD
Annual income on $10K today (after 15% tax)
$12,056.74/yr
After 10yr DRIP, annual income (after tax)
$6,721,285.61/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SVFD beats the other by $6,698,965.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SVFD + PFE for your $10,000?

SVFD: 50%PFE: 50%
100% PFE50/50100% SVFD
Portfolio after 10yr
$9.46M
Annual income
$3,966,826.78/yr
Blended yield
41.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SVFD
No analyst data
Altman Z
-583.3
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SVFD buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSVFDPFE
Forward yield141.84%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$18.87M$49.6K
Annual income after 10y$7,907,394.84$26,258.71
Total dividends collected$17.39M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SVFD vs PFE ($10,000, DRIP)

YearSVFD PortfolioSVFD Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$24,884$14,184.40$9,153$693.39+$15.7KSVFD
2$59,614$32,987.87$8,593$849.25+$51.0KSVFD
3$137,644$73,857.20$8,336$1,066.78+$129.3KSVFD
4$306,654$159,374.19$8,437$1,384.80+$298.2KSVFD
5$659,956$331,836.32$9,013$1,875.40+$650.9KSVFD
6$1,373,584$667,431.66$10,306$2,680.72+$1.36MSVFD
7$2,768,001$1,298,265.55$12,820$4,101.38+$2.76MSVFD
8$5,406,827$2,445,066.30$17,673$6,826.70+$5.39MSVFD
9$10,248,883$4,463,578.15$27,543$12,591.86+$10.22MSVFD
10$18,873,700$7,907,394.84$49,560$26,258.71+$18.82MSVFD

SVFD vs PFE: Complete Analysis 2026

SVFDStock

Save Foods, Inc., an agri-food tech company, develops and sells eco-friendly green treatments for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with oxidizing agent-based sanitizers for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Pimi Agro Cleantech, Inc. and changed its name to Save Foods, Inc. in April 2016. Save Foods, Inc. was incorporated in 2009 and is based in Miami, Florida.

Full SVFD Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SVFD vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SVFD vs SCHDSVFD vs JEPISVFD vs OSVFD vs KOSVFD vs MAINSVFD vs JNJSVFD vs MRKSVFD vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.